Because these transmembrane ligands have been shown to activate Erk and Akt, the pathways we identified as activated in CD97-expressing GBM cells, we cannot draw conclusions about which ligands are used by CD97 in GBM based on our signaling findings. The gene discussed is AKT1; the disease is glioblastoma.